Nuveen Asset Management LLC Sells 114,138 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Nuveen Asset Management LLC decreased its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 38.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 183,761 shares of the company's stock after selling 114,138 shares during the period. Nuveen Asset Management LLC owned 0.25% of SpringWorks Therapeutics worth $6,639,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Barclays PLC lifted its holdings in SpringWorks Therapeutics by 60.4% in the 3rd quarter. Barclays PLC now owns 155,676 shares of the company's stock valued at $4,987,000 after acquiring an additional 58,645 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of SpringWorks Therapeutics in the 4th quarter worth approximately $210,000. KBC Group NV lifted its stake in SpringWorks Therapeutics by 59.1% during the fourth quarter. KBC Group NV now owns 2,634 shares of the company's stock valued at $95,000 after purchasing an additional 978 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in SpringWorks Therapeutics by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 15,773 shares of the company's stock valued at $570,000 after purchasing an additional 1,488 shares during the last quarter. Finally, Rhumbline Advisers grew its position in SpringWorks Therapeutics by 2.3% in the fourth quarter. Rhumbline Advisers now owns 101,904 shares of the company's stock worth $3,682,000 after buying an additional 2,251 shares during the last quarter.

SpringWorks Therapeutics Stock Up 0.2%

Shares of SWTX traded up $0.08 during mid-day trading on Tuesday, hitting $46.75. 3,199,718 shares of the company's stock were exchanged, compared to its average volume of 2,247,864. The stock has a market cap of $3.52 billion, a price-to-earnings ratio of -13.43 and a beta of 0.77. The firm has a fifty day moving average of $43.27 and a two-hundred day moving average of $43.35. SpringWorks Therapeutics, Inc. has a twelve month low of $28.21 and a twelve month high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The business had revenue of $49.09 million during the quarter, compared to the consensus estimate of $64.19 million. On average, equities analysts predict that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on SWTX. Guggenheim reissued a "neutral" rating and issued a $47.00 price target on shares of SpringWorks Therapeutics in a research note on Monday, May 12th. Wedbush reissued a "neutral" rating and issued a $47.00 target price (down from $81.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th. Barclays reissued an "equal weight" rating and set a $47.00 target price (down from $63.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Evercore ISI lowered SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. Finally, HC Wainwright reiterated a "neutral" rating and set a $47.00 price target (down previously from $74.00) on shares of SpringWorks Therapeutics in a report on Wednesday, April 30th. Seven investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, SpringWorks Therapeutics presently has an average rating of "Hold" and an average price target of $52.57.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.